bpc-157 fda status warning letter compounding FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Officials shed light on non-FDA

Container Type: Type I borosilicate glass vial, aluminium crimp with flip-off cap

the clinical relevance of this finding in humans is unknown, and in UK and EU prescribing information this is noted as a precaution rather than a formal contraindication but individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their doctor

A guideline-based cardiovascular threshold may instead identify a level at which risk changes or treatment should be discussed

C.YoungJ.et al (2001)

Longevity bio-regulator

Complete dosing chart at 10mg/ml (1ml of bacteriostatic water) Notice the problem at the 1.25mg microdose level